Delcath Systems Inc
DCTH10.070USD
0.000
Market hours （ET）Quotes delayed by 15 min
355.56MMarket Cap
225.89P/E TTM
More Details of Delcath Systems Inc Company
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Delcath Systems Inc Info
Ticker SymbolDCTH
Company nameDelcath Systems Inc
IPO dateOct 19, 2000
CEOMichel (Gerard J)
Number of employees96
Security typeOrdinary Share
Fiscal year-endOct 19
Address566 Queensbury Avenue
CityQUEENSBURY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code12804
Phone15187438892
Websitehttps://delcath.com/
Ticker SymbolDCTH
IPO dateOct 19, 2000
CEOMichel (Gerard J)
Company Executives of Delcath Systems Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Chief Executive Officer, Director
Chief Executive Officer, Director
330.83K
+3.60%
Ms. Sandra Pennell
Ms. Sandra Pennell
Chief Financial Officer
Chief Financial Officer
70.30K
+15.15%
Mr. Kevin Muir
Mr. Kevin Muir
General Manager - Interventional Oncology
General Manager - Interventional Oncology
21.61K
+16.30%
Mr. John Richard Sylvester
Mr. John Richard Sylvester
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
14.94K
+41.57%
Ms. Martha S. Rook, Ph.D.
Ms. Martha S. Rook, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Hoffman
Mr. David Hoffman
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Dr. Vojislav Vukovic, M.D., Ph.D.
Dr. Vojislav Vukovic, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Mr. Steven A.J. Salamon
Mr. Steven A.J. Salamon
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Chief Executive Officer, Director
Chief Executive Officer, Director
330.83K
+3.60%
Ms. Sandra Pennell
Ms. Sandra Pennell
Chief Financial Officer
Chief Financial Officer
70.30K
+15.15%
Mr. Kevin Muir
Mr. Kevin Muir
General Manager - Interventional Oncology
General Manager - Interventional Oncology
21.61K
+16.30%
Mr. John Richard Sylvester
Mr. John Richard Sylvester
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
14.94K
+41.57%
Ms. Martha S. Rook, Ph.D.
Ms. Martha S. Rook, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Hoffman
Mr. David Hoffman
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
By BusinessUSD
Name
Revenue
Proportion
HEPZATO KIT
22.50M
93.14%
CHEMOSAT
1.66M
6.86%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
HEPZATO KIT
22.50M
93.14%
CHEMOSAT
1.66M
6.86%
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rosalind Advisors, Inc.
9.35%
The Vanguard Group, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.50%
Simplify Asset Management Inc
1.98%
Geode Capital Management, L.L.C.
1.95%
Other
77.53%
Shareholders
Shareholders
Proportion
Rosalind Advisors, Inc.
9.35%
The Vanguard Group, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.50%
Simplify Asset Management Inc
1.98%
Geode Capital Management, L.L.C.
1.95%
Other
77.53%
Shareholder Types
Shareholders
Proportion
Hedge Fund
20.47%
Investment Advisor
17.51%
Investment Advisor/Hedge Fund
8.95%
Venture Capital
2.90%
Individual Investor
2.74%
Research Firm
2.40%
Pension Fund
0.35%
Bank and Trust
0.09%
Insurance Company
0.03%
Other
44.55%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
238
18.04M
62.08%
+1.07K
2025Q3
242
18.04M
64.94%
-422.09K
2025Q2
221
18.52M
54.81%
+2.84M
2025Q1
160
15.18M
51.87%
-2.16M
2024Q4
134
13.70M
43.13%
+3.02M
2024Q3
103
10.42M
51.90%
-86.02K
2024Q2
84
10.50M
46.11%
+479.32K
2024Q1
71
8.41M
37.64%
-1.16M
2023Q4
72
6.53M
41.36%
-1.60M
2023Q3
66
8.03M
51.77%
+1.12M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rosalind Advisors, Inc.
3.30M
9.43%
-113.08K
-3.31%
Jun 30, 2025
The Vanguard Group, Inc.
1.61M
4.6%
+216.71K
+15.55%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.56M
4.45%
+1.39M
+821.60%
Jun 30, 2025
Geode Capital Management, L.L.C.
703.17K
2.01%
+394.90K
+128.10%
Jun 30, 2025
State Street Investment Management (US)
473.89K
1.35%
+360.15K
+316.63%
Jun 30, 2025
Vivo Capital, LLC
569.53K
1.63%
-180.67K
-24.08%
Jun 30, 2025
Citadel Advisors LLC
803.21K
2.3%
+677.66K
+539.74%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
3.79%
ALPS Medical Breakthroughs ETF
0.14%
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
View more
Simplify Propel Opportunities ETF
Proportion3.79%
ALPS Medical Breakthroughs ETF
Proportion0.14%
iShares Micro-Cap ETF
Proportion0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
iShares Russell 2000 Growth ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Delcath Systems Inc?
The top five shareholders of Delcath Systems Inc are:
Rosalind Advisors, Inc. holds 3.30M shares, accounting for 9.43% of the total shares.
The Vanguard Group, Inc. holds 1.61M shares, accounting for 4.60% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.56M shares, accounting for 4.45% of the total shares.
Geode Capital Management, L.L.C. holds 703.17K shares, accounting for 2.01% of the total shares.
State Street Investment Management (US) holds 473.89K shares, accounting for 1.35% of the total shares.
Rosalind Advisors, Inc. holds 3.30M shares, accounting for 9.43% of the total shares.
The Vanguard Group, Inc. holds 1.61M shares, accounting for 4.60% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.56M shares, accounting for 4.45% of the total shares.
Geode Capital Management, L.L.C. holds 703.17K shares, accounting for 2.01% of the total shares.
State Street Investment Management (US) holds 473.89K shares, accounting for 1.35% of the total shares.
What are the top three shareholder types of Delcath Systems Inc?
The top three shareholder types of Delcath Systems Inc are:
Rosalind Advisors, Inc.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Rosalind Advisors, Inc.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Delcath Systems Inc (DCTH)?
As of 2025Q4, 238 institutions hold shares of Delcath Systems Inc, with a combined market value of approximately 18.04M, accounting for 62.08% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.85%.
What is the biggest source of revenue for Delcath Systems Inc?
In FY2025Q2, the HEPZATO KIT business generated the highest revenue for Delcath Systems Inc, amounting to 22.50M and accounting for 93.14% of total revenue.
